Welcome to our dedicated page for Accuray Incorp SEC filings (Ticker: ARAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Accuray’s radiation oncology business is packed with regulatory nuance—each 10-K page covers FDA clearances, global supply chains, and service-contract margins. Finding R&D spend or tracking when executives trade shares should not require hours with spreadsheets. That’s why our SEC filings hub brings Accuray insider trading Form 4 transactions and every other disclosure into one streamlined view.
Stock Titan’s AI reads the fine print for you. Open an Accuray quarterly earnings report 10-Q filing and our algorithms instantly surface backlog changes, CyberKnife unit shipments, and reimbursement commentary. Get Accuray Form 4 insider transactions real-time alerts, side-by-side with revenue trend graphs. Whether you’re understanding Accuray SEC documents with AI for due diligence or need an Accuray annual report 10-K simplified, we translate technical jargon into clear business drivers.
Every filing type is here and searchable: 8-Ks for product-recall updates—see “Accuray 8-K material events explained”—DEF 14A for Accuray proxy statement executive compensation, and of course Form 4 for Accuray executive stock transactions Form 4. Use our AI-powered summaries to compare quarter-over-quarter margin shifts, monitor clinical-trial timelines, and flag warranty reserve changes. With comprehensive coverage, real-time EDGAR pulls, and plain-English insights, you’ll move from document download to actionable perspective in minutes while enjoying Accuray SEC filings explained simply and fast Accuray earnings report filing analysis.
Accuray Incorporated updated its financing and launched a major restructuring as part of a broader transformation plan. The company amended its loan agreement to allow certain restricted cash to count toward Liquidity, remove the leverage condition for drawing on its delayed draw term loan facility, reduce delayed draw commitments to $18.25 million, and postpone testing of total leverage and fixed charge coverage covenants until the fiscal quarter ending December 31, 2026. Accuray also agreed to higher prepayment premiums, additional premiums totaling $1.9 million, and a $5 million temporary reduction in revolving credit availability through that date.
To induce lenders to enter into these changes, Accuray issued unregistered warrants for specified numbers of common shares at exercise prices of $1.50, $1.25 and $0.01 per share, expiring on December 15, 2032, and provided for additional warrants if delayed draw loans are funded, all with price-protection anti-dilution features. Separately, the company began the first phase of a strategic and organizational transformation, eliminating about 15 percent of its global workforce. It expects approximately $5.4 million in headcount-related restructuring costs and $5.6 million from other initiatives, for total charges of about $11 million across fiscal 2026, and disclosed that this first phase is expected to improve annualized operating profitability by approximately $25 million.
Accuray Inc. (ARAY)11/21/2025, 56,603 restricted stock units (RSUs) were converted into shares of Accuray common stock at an exercise price of $0, coded as an "M" transaction (option or derivative conversion).
After this conversion, Whitters beneficially owns 667,656 shares of Accuray common stock in direct ownership. Each RSU represents a contingent right to receive one share of common stock, and this RSU grant was structured to vest 100% on 11/21/2025, triggering the share issuance reported here.
Accuray Inc. (ARAY) director reports equity transactions in a Form 4. On 11/21/2025, the director settled 56,603 restricted stock units (RSUs), receiving the same number of shares of Accuray common stock at an exercise price of $0. On the same date, 22,642 shares of common stock were disposed of at $1.05 per share, described as shares forfeited due to a cash settlement election made in the grant agreement. After these transactions, the director beneficially owned 153,294 shares of Accuray common stock, held directly.
Accuray Inc. director transaction: A director of Accuray Inc. (ARAY) reported the vesting and settlement of 56,603 restricted stock units (RSUs) into shares of common stock on 11/21/2025. The RSUs converted at an exercise price of $0, meaning the director did not pay cash to receive the shares. Each RSU represented the right to receive one share of Accuray common stock and this RSU grant vested 100% on that date. Following this transaction, the director beneficially owned 212,659 shares of Accuray common stock in direct ownership.
Accuray Inc. director reports RSU vesting and share acquisition
A director of Accuray Inc. (ARAY) reported the vesting and settlement of restricted stock units into common stock. On 11/21/2025, 45,620 restricted stock units converted into 45,620 shares of Accuray common stock at an exercise price of $0, reported with transaction code "M," which indicates a derivative-to-equity conversion. Following this transaction, the director beneficially owns 400,229 shares of Accuray common stock in direct form. The reported restricted stock units were a grant that was scheduled to vest 100% on 11/21/2025, with each unit representing the right to receive one share of common stock.
Accuray Inc. director reports RSU vesting and share acquisition
A director of Accuray Inc. (ARAY), Anne Bryce Le Grand, reported the vesting of restricted stock units and related share acquisition. On 11/21/2025, 56,603 restricted stock units were converted to the same number of shares of Accuray common stock at an exercise price of $0, reported under transaction code "M." Each RSU represented a contingent right to receive one share of common stock and this RSU award vested 100% on that date.
Following this transaction, the reporting person beneficially owns 259,499 shares of Accuray common stock in direct form and no longer holds any of the reported derivative RSUs. This filing is a routine disclosure of insider equity compensation activity and ownership under the securities rules.
Accuray Inc. (ARAY) director Beverly A. Huss reported equity transactions involving company stock. On 11/21/2025, a grant of 56,603 restricted stock units (RSUs) was settled into an equivalent number of common shares at an exercise price of $0 per share. On the same date, 22,642 shares were forfeited, as noted, due to a cash settlement election made by the director in the grant agreement at a reported price of $1.05 per share. Following these transactions, the director directly beneficially owned 221,323 shares of Accuray common stock.
Each RSU represents a contingent right to receive one share of Accuray common stock, and the referenced RSU grant was scheduled to vest 100% on 11/21/2025.
Accuray Inc. (ARAY) director reports RSU vesting and share acquisition. A company director filed a Form 4 disclosing the conversion of 56,603 restricted stock units (RSUs) into an equal number of shares of Accuray common stock on 11/21/2025 through a transaction coded “M” (option or derivative exercise). The RSUs had an exercise price of $0, meaning the director did not pay cash to receive the shares. After this transaction, the director beneficially owns 294,804 shares of Accuray common stock in direct ownership. Each RSU represented a contingent right to receive one share, and this RSU grant vested 100% on 11/21/2025.
Accuray Incorporated filed a Form S-8 registration statement to register shares of its common stock for issuance under the Accuray Incorporated 2026 Equity Incentive Plan
The filing incorporates by reference Accuray’s latest Annual Report on Form 10-K for the year ended June 30, 2025, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, recent Current Reports on Form 8-K, and the existing description of its common stock. It also describes the company’s Delaware-law based indemnification protections for directors and officers, including charter and bylaw provisions, separate indemnification agreements, and directors’ and officers’ liability insurance.
Accuray Inc. (ARAY) CEO and director Stephen R. La Neve reported an open-market purchase of 20,000 shares of common stock on 11/19/2025. The transaction was reported at a weighted average purchase price of $0.9705 per share, with individual trades executed between $0.9699 and $0.9708. Following this purchase, La Neve beneficially owns 20,000 shares directly. The filing notes that detailed trade-by-trade pricing information within the stated range is available upon request.
FAQ
What is the current stock price of Accuray Incorp (ARAY)?
What is the market cap of Accuray Incorp (ARAY)?
